- Mijovic, A. and Mufti, G.J. (1999) "Management of the myelodysplastic syndromes", CME Bulletin Haematology 2 (1), 3 - 6
- Morosetti, R. and Koeffler, H.P. (1996) "Differentiation therapy in myelodysplastic syndromes", Seminars in Hematology 33 (3), 236 - 245
- Nagler, A., Ricklis, I., Gazit, E., Tatarsky, I. and Fabian, I. (1986) "Differentiation of bone marrow cells from myelodysplastic patients in the presence of 1,25 dihydroxyvitamin D3 or 13-cis retinoic acid", European Journal of Clinical Investigation 16 (4), 297 - 301
- Kizaki, M. and Koeffler, H.P. (1992) "Differentiation-inducing agents in the treatment of myelodysplastic syndromes", Seminars in Oncology 19 (1), 95 - 105
- Richard, C., Mazo, E., Cuadrado, M.A., Iriondo, A., Bello, C., Gandarillas, M.A. and Zubizarreta, A. (1986) "Treatment of myelodysplastic syndrome with 1,25-dihydroxy-vitamin D3", American Journal of Hematology 23 (2), 175 - 178
- De Rosa, L., Montuoro, A. and De Laurenzi, A. (1992) "Therapy of high risk myelodysplastic syndromes with an association of low-dose Ara-C, retinoic acid and 1,25-dihydroxyvitamin D3", Biomedicine and Pharmacotherapy 46 (5-7), 211 - 217
- Mellibovsky, L., Diez, A., Perez-Vila, E., Serrano, S., Nacher, M., Aubia, J., Supervia, A. and Recker, R.R. (1998) "Vitamin D treatment in myelodysplastic syndromes", British Journal of Haematology 100 (3), 516 - 520
- Raya Sanchez, J.M., Hernandez Nieto, L., Brito Barroso, M.L. and Hernandez Garcia, M.T. (1994) "The beneficial effect of 1,25-dihydroxycholecalciferol on the excess of blasts and the myelofibrosis in 2 cases of chronic myeloproliferative syndrome", Medicina Clinica 102 (10), 380 - 382
- Pagliuca, A., Layton, D.M., Manoharan, A., Gordon, S., Green, P.J. and Mufti, G.J. (1989) "Myelofibrosis in primary myelodysplastic syndromes: a clinico-morphological study of 10 cases", British Journal of Haematology 71 (4), 499 - 504
Leukemia & Lymphoma
Volume 43, 2002 - Issue 7